Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2015 to Q4 2025

Type / Class
Equity / Ordinary Shares, nominal value EUR0.05 per share
Symbol
CLLS on Nasdaq
Shares outstanding
95,490,450
Price per share
$4.06
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
10,548,060
Total reported value
$51,052,315
% of total 13F portfolios
0%
Share change
+2,020,139
Value change
+$10,425,733
Number of holders
34
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ASTRAZENECA PLC 44% $66,440,000 44,000,000 AstraZeneca PLC 23 Jan 2025
Bpifrance Participations SA 11% -15% $33,176,247 +$960,243 10,599,440 +3% Caisse des Depots 03 Dec 2025
Long Focus Capital Management, LLC 4.6% $6,972,112 4,617,293 LONG FOCUS CAPITAL MANAGEMENT, LLC 31 Dec 2024

As of 31 Dec 2025, 34 institutional investors reported holding 10,548,060 shares of Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS). This represents 11% of the company’s total 95,490,450 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS) together control 11% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
B Group, Inc. 3.4% 3,281,501 0% 12% $15,882,465
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 3.3% 3,178,620 0% $15,384,521
Long Focus Capital Management, LLC 2.9% 2,787,750 -32% 0.68% $13,492,710
BlackRock, Inc. 0.4% 384,299 0% $1,860,007
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 0.24% 226,875 0% 0% $1,098,000
MARSHALL WACE, LLP 0.19% 178,473 +1610% 0% $863,809
CITADEL ADVISORS LLC 0.1% 95,427 -57% 0% $461,867
MORGAN STANLEY 0.09% 87,176 -0.57% 0% $421,932
LPL Financial LLC 0.09% 84,792 -0.42% 0% $410,393
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.05% 52,423 -2.7% 0% $253,727
UBS Group AG 0.05% 50,100 +71% 0% $242,484
BNP PARIBAS FINANCIAL MARKETS 0.04% 41,300 0% 0% $199,892
Point72 Asset Management, L.P. 0.03% 27,314 0% $132,200
Delaney Dennis R 0.03% 24,000 0% 0.06% $116,160
RHUMBLINE ADVISERS 0.01% 13,343 +817% 0% $64,575
Global Retirement Partners, LLC 0.01% 7,038 0% $34,064
HARBOUR INVESTMENTS, INC. 0% 4,500 0% 0% $21,780
NATIONAL BANK OF CANADA /FI/ 0% 3,600 0% 0% $17,208
BANK OF AMERICA CORP /DE/ 0% 3,514 +4464% 0% $17,008
WELLS FARGO & COMPANY/MN 0% 3,150 0% 0% $15,246
QUADRANT CAPITAL GROUP LLC 0% 2,761 0% $13,364
CITIGROUP INC 0% 2,558 +158% 0% $12,381
Atlantic Union Bankshares Corp 0% 1,500 0% 0% $7,260
Parallel Advisors, LLC 0% 1,479 0% $7,158
Tower Research Capital LLC (TRC) 0% 1,133 0% $5,484

Institutional Holders of Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 10,548,060 $51,052,315 +$10,425,733 $4.84 34
2025 Q3 8,311,195 $23,687,285 -$5,592,819 $2.85 28
2025 Q2 11,757,728 $17,853,958 -$2,754,141 $1.52 24
2025 Q1 13,602,212 $16,864,343 -$51,496 $1.24 27
2024 Q4 12,759,251 $22,964,294 -$366,691 $1.80 29
2024 Q3 9,766,379 $20,863,531 -$17,239 $2.14 27
2024 Q2 9,772,625 $18,275,141 +$2,408,132 $1.87 27
2024 Q1 9,854,602 $26,115,627 +$90,284 $2.65 31
2023 Q4 9,816,725 $30,235,236 -$3,425,688 $3.08 33
2023 Q3 11,480,546 $18,138,183 -$4,873,642 $1.58 28
2023 Q2 14,008,673 $27,590,926 -$2,313,872 $1.97 31
2023 Q1 15,157,594 $29,256,650 +$12,430,028 $1.93 29
2022 Q4 8,733,333 $18,344,069 -$3,514,674 $2.10 37
2022 Q3 10,299,547 $23,616,856 -$1,469,623 $2.29 43
2022 Q2 10,831,048 $30,655,602 -$4,582,029 $2.83 39
2022 Q1 12,267,940 $55,746,674 -$33,254,202 $4.54 45
2021 Q4 15,187,964 $123,726,723 -$17,963,859 $8.12 55
2021 Q3 15,388,771 $194,068,172 -$11,531,807 $12.61 65
2021 Q2 16,213,399 $250,623,262 +$15,081,703 $15.47 71
2021 Q1 15,242,452 $308,003,839 -$24,336,115 $20.21 78
2020 Q4 16,303,634 $441,619,228 +$62,320,026 $27.06 83
2020 Q3 14,221,535 $263,393,288 +$6,612,668 $18.50 70
2020 Q2 13,884,259 $246,854,298 -$7,256,587 $17.80 77
2020 Q1 14,368,296 $132,185,088 +$10,383,968 $9.20 60
2019 Q4 13,222,126 $226,376,965 +$2,249,267 $17.12 56
2019 Q3 13,148,118 $136,738,200 -$8,890,725 $10.40 60
2019 Q2 13,435,563 $209,551,644 +$8,545,734 $15.60 66
2019 Q1 12,740,024 $233,652,737 +$24,305,612 $18.34 61
2018 Q4 11,487,097 $191,259,158 -$7,897,776 $16.65 62
2018 Q3 11,517,705 $325,035,828 +$5,780,905 $28.22 78
2018 Q2 11,275,435 $319,022,621 +$114,519,929 $28.29 82
2018 Q1 7,051,580 $222,126,151 -$5,958,926 $31.51 67
2017 Q4 7,308,253 $213,043,133 +$42,490,371 $29.15 55
2017 Q3 5,872,301 $167,046,670 +$17,699,694 $28.45 41
2017 Q2 5,258,779 $135,752,000 -$10,905,829 $25.82 39
2017 Q1 5,703,192 $136,879,000 +$1,857,397 $24.00 39
2016 Q4 5,670,274 $96,110,000 -$23,068,115 $16.95 36
2016 Q3 6,638,753 $159,861,000 -$772,505 $24.08 38
2016 Q2 6,932,847 $184,344,000 +$12,602,577 $26.59 38
2016 Q1 6,465,692 $177,790,378 -$18,348,502 $27.50 43
2015 Q4 7,051,276 $218,793,000 +$7,781,538 $31.03 47
2015 Q3 6,877,612 $181,305,000 +$7,208,463 $26.36 43
2015 Q2 6,601,328 $238,170,032 +$18,429,242 $36.08 40
2015 Q1 6,124,463 $211,832,000 +$211,832,000 $34.59 44